Byline: Market Analysis & Forecast Aurinia Pharmaceuticals is one of the more fascinating biotech setups in the market right now. Why? Because the company has something rare for a small-cap biotech : 👉 a commercially approved drug generating real revenue and real cash flow But the market still treats it like a speculative story. Recent CEO commentary has focused on: expanding adoption of LUPKYNIS improving physician awareness long-term growth in lupus nephritis treatment And if management is right, the market may be dramatically underestimating how large this opportunity could become. The News: Commercial Momentum Is Building Aurinia’s core product, LUPKYNIS , treats lupus nephritis—a severe autoimmune kidney disease . Leadership continues emphasizing: increasing prescription trends expanding patient access long-term penetration opportunity Why This Matters Lupus nephritis is: chronic serious underserved 👉 Effective long-term treatments co...